Allegria Therapeutics Raises $5.1 Million to Advance Mast Cell-Targeted Therapies for Allergic Diseases
核心洞察
Allegria Therapeutics (搜索), a Basel-based biotech company, has secured $5.1 million in seed extension funding led by ALK-Abelló to advance its mast cell-mediated disease pipeline.
The company is developing first-in-class therapeutic approaches that selectively modulate mast cells to treat allergies and inflammatory conditions affecting hundreds of millions globally.
Founded in 2023, Allegria aims to nominate its first clinical candidate while expanding discovery programs targeting uncontrolled mast cell activation pathways.
Allegria Therapeutics (搜索) has closed a $5.1 million seed extension financing to accelerate development of novel therapies targeting mast cell-mediated diseases, positioning the Basel-based biotechnology company to advance its lead program toward clinical candidate nomination. The round was led by ALK-Abelló, with participation from HighLight Capital (搜索), Lichtsteiner Foundation, and co-founding investor Forty51 Ventures (搜索).
Strategic Focus on Mast Cell Modulation
Founded in 2023, Allegria is building a portfolio of proprietary therapeutic approaches designed to selectively modulate mast cells, with a primary focus on allergies and related inflammatory conditions. The company has identified molecules it believes could support first-in-class and best-in-disease potential across multiple indications tied to uncontrolled mast cell activation.
"Precision approaches offer the ability to target defined cell types and pathways to disrupt the pathogenic biology driving disease with optimal efficacy and safety," said Maria van Dongen, Ph.D., Co-founder and CEO of Allegria. "By identifying the relevant pathways and targets in uncontrolled mast cell activation, and leveraging our extensive experience in drug development, we aim to bring more and better options to patients across numerous allergic and inflammatory diseases."
Partnership with ALK-Abelló Strengthens Development Pipeline
The financing deepens Allegria's relationship with ALK-Abelló, a specialty pharmaceutical company focused on allergy and allergic asthma. As part of the investment, Dr. Peter Sejer Andersen has joined Allegria's board as a non-executive director, bringing additional expertise to the company's strategic direction.
"Every year hundreds of millions are impacted by allergy, affecting their daily lives and potentially causing life threatening situations," said Peter Sejer Andersen, Ph.D., Senior Vice President of Global Research and Drug Discovery at ALK. "Building on our strong heritage, our mission is to help five million people every year by 2030 through innovative and more effective solutions. We have followed ALLEGRIA's development and have been repeatedly impressed with their advancements and team, as well as their highly original strategy for novel treatments for allergic disorders."
Academic Collaborations Support Discovery Efforts
Allegria has established collaborations with academic and clinical partners to support mast cell biology research, drug discovery, and preclinical evaluation. Key partnerships include Prof. Dr. Martin Metz at Charité's Institute for Allergology in Berlin and Ap. Prof. Dr. Philipp Starkl at the Medical University of Vienna, providing the company with access to specialized expertise in mast cell research and allergic disease mechanisms.
Addressing Unmet Medical Needs
The new capital will be used to progress Allegria's lead program toward preclinical candidates and nominate its first clinical candidate, while also advancing discovery-stage programs. The company has assembled an experienced core team and advisory board to support its development efforts in addressing the significant burden of allergic and inflammatory diseases.
"We are excited to be able to invest in ALLEGRIA, as the company is an excellent example of first-in-class therapeutic innovations that could significantly reduce the burden of several chronic diseases," noted an investor representative. "Growing scientific and clinical insight shows that mast cells play an important role in a range of human pathologies."